Randomized double-blind placebo-controlled crossover study of caffeine in patients with intermittent claudication

被引:13
|
作者
Momsen, A. H. [3 ]
Jensen, M. B. [1 ]
Norager, C. B. [3 ]
Madsen, M. R. [3 ]
Vestersgaard-Andersen, T. [2 ]
Lindholt, J. S. [2 ]
机构
[1] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark
[2] Reg Hosp Viborg, Dept Vasc Surg, Vasc Surg Res Unit, Viborg, Denmark
[3] Reg Hosp Herning, Surg Res Units, Dept Surg, DK-7400 Herning, Denmark
关键词
PERIPHERAL ARTERIAL-DISEASE; TREADMILL EXERCISE; PHYSICAL-ACTIVITY; METABOLISM; ENDURANCE; REPRODUCIBILITY; METAANALYSIS; INGESTION; CITIZENS; WALKING;
D O I
10.1002/bjs.7149
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Intermittent claudication is a disabling symptom of peripheral arterial disease for which few medical treatments are available. This study investigated the effect of caffeine on physical capacity in patients with intermittent claudication. Methods: This randomized double-blind placebo-controlled crossover study included 88 patients recruited by surgeons from outpatient clinics. The participants abstained from caffeine for 48 h before each test and then received either a placebo or oral caffeine (6 mg/kg). After 75 min, pain-free and maximal walking distance on a treadmill, perceived pain, reaction times, postural stability, maximal isometric knee extension strength, submaximal knee extension endurance and cognitive function were measured. The analysis was by intention to treat. Results: Caffeine increased the pain-free walking distance by 20.0 (95 per cent confidence interval 3.7 to 38.8) per cent (P = 0.014), maximal walking distance by 26.6 (12.1 to 43.0) per cent (P < 0.001), muscle strength by 9.8 (3.0 to 17.0) per cent (P = 0.005) and endurance by 21.4 (1.2 to 45.7) per cent (P = 0.004). However, postural stability was reduced significantly, by 22.1 (11.7 to 33.4) per cent with eyes open (P < 0.001) and by 21.8 (7.6 to 37.8) per cent with eyes closed (P = 0.002). Neither reaction time nor cognition was affected. Conclusion: In patients with moderate intermittent claudication, caffeine increased walking distance, maximal strength and endurance, but affected balance adversely. Registration number: NCT00388128 (http://www.clinicaltrials.gov).
引用
收藏
页码:1503 / 1510
页数:8
相关论文
共 50 条
  • [11] Effects of caffeine as an adjuvant to morphine in advanced cancer patients: A randomized, double-blind, placebo-controlled, crossover study
    Mercadante, S
    Serretta, R
    Casuccio, A
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 21 (05) : 369 - 372
  • [12] Metabolic and hormonal effects of caffeine: randomized, double-blind, placebo-controlled crossover trial
    MacKenzie, Todd
    Comi, Richard
    Sluss, Patrick
    Keisari, Ronit
    Manwar, Simone
    Kim, Janice
    Larson, Robin
    Baron, John A.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (12): : 1694 - 1698
  • [13] PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF KETANSERIN IN TREATMENT OF INTERMITTENT CLAUDICATION
    DECREE, J
    GEUKENS, H
    LEEMPOELS, J
    VERHAEGEN, H
    [J]. LANCET, 1984, 2 (8406): : 775 - 779
  • [14] PLACEBO-CONTROLLED, DOUBLE-BLIND COMPARISON OF NICARDIPINE AND CAPTOPRIL IN NORMOTENSIVE PATIENTS WITH INTERMITTENT CLAUDICATION
    BERNARDI, D
    BARTOLI, P
    FERRERI, A
    GERI, AB
    IERI, A
    [J]. ADVANCES IN VASCULAR PATHOLOGY 1989, VOLS 1 & 2, 1989, 868 : 807 - 814
  • [15] PLACEBO-CONTROLLED, DOUBLE-BLIND COMPARISON OF NICARDIPINE AND CAPTOPRIL IN NORMOTENSIVE PATIENTS WITH INTERMITTENT CLAUDICATION
    BERNARDI, D
    BARTOLI, P
    FERRERI, A
    GERI, AB
    LERI, A
    [J]. GERIATRIC CARDIOVASCULAR MEDICINE, 1988, 1 (04): : 277 - 281
  • [16] DOUBLE-BLIND, CONTROLLED, MULTICENTER STUDY OF INDOBUFEN VERSUS PLACEBO IN PATIENTS WITH INTERMITTENT CLAUDICATION
    TONNESEN, KH
    ALBUQUERQUE, P
    BAITSCH, G
    ALONSO, AG
    IBANEZ, F
    KESTER, RC
    LEVESON, S
    POREDOS, P
    [J]. INTERNATIONAL ANGIOLOGY, 1993, 12 (04) : 371 - 377
  • [17] Heparan sulfate in the treatment of intermittent claudication: Results of a randomized, double-blind, placebo-controlled multicenter trial
    Messa, GL
    Gelso, E
    [J]. DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 2002, 28 (01) : 37 - 48
  • [18] Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study
    Pomier-Layrargues, G
    Paquin, SC
    Hassoun, Z
    Lafortune, M
    Tran, A
    [J]. HEPATOLOGY, 2003, 38 (01) : 238 - 243
  • [19] A randomized, double-blind, placebo-controlled crossover study on oral ATP administration
    Coolen, Erik
    Arts, Ilja
    Bours, Martijn
    Huyghebaert, Nathalie
    Cohen, Stuart Martien
    Bast, Aalt
    Dagnelie, Pieter
    [J]. PURINERGIC SIGNALLING, 2008, 4 : S196 - S197
  • [20] Estradiol in premenstrual asthma: A double-blind, randomized, placebo-controlled, crossover study
    Ensom, MHH
    Chong, G
    Zhou, DY
    Beaudin, B
    Shalansky, S
    Bai, TR
    [J]. PHARMACOTHERAPY, 2003, 23 (05): : 561 - 571